India to mass produce of COVID-19 vaccine: Health Minister
ECONOMY & POLICY

India to mass produce of COVID-19 vaccine: Health Minister

Union Minister of Health & Family Welfare, Minister of Science & Technology and Minister of Earth Sciences, Dr. Harsh Vardhan has said that as the world raced to develop a COVID-19 vaccine, India was look...

Union Minister of Health & Family Welfare, Minister of Science & Technology and Minister of Earth Sciences, Dr. Harsh Vardhan has said that as the world raced to develop a COVID-19 vaccine, India was looking to become self-reliant in both its development and mass production. Addressing the virtual Global R&D Summit 2020, organised by the industry chamber, Federation of Indian Chambers of Commerce & Industry (FICCI), jointly with the Department of Science and Technology (DST), on November 25, Dr. Vardhan said, “Called as the ‘pharmacy of the world’, India has the largest capacity to produce COVID-19 vaccines. We have now started to look at a robust vaccine manufacturing and delivery ecosystem to meet our demands in the coming days. That is one area where your (industry’s) input will help us in not only addressing a topical issue but also creating best practices for the future.” Terming research and innovation as a way of life, the minister observed, “The current pandemic has only reinforced our belief in innovation and R&D to accelerate products and services that not only are helping in disease management but in turn to make our nation resilient and self-reliant.” He further stated that it was time for taking bold decisions and investments, and not for adopting conservative approaches for building competitive global supply chains. “This also is the time to move from a command-and-control economy to plug-and-play and to build a competitive global supply chain. We are committed to help companies invest in India and make for India and the world,” he emphasised. Fuelled by the current pandemic, Dr. Vardhan said that India was transitioning from an era of liberalisation and globalisation to one where it must reinvent itself to become a self-reliant country. Presently, three vaccines are in various stages of clinical trials in the country. Oxford University vaccine being developed with AstraZeneca is in the third phase of trials at Pune’s Serum Institute. Expected for release by January 2021, Serum Institute will be responsible for its distribution. Dr. Reddy’s Laboratories is testing the Russian Direct Investment Fund (RDIF)’s Sputnik V vaccine. It has entered into a partnership with the Biotechnology Industry Research Assistance Council (BIRAC) of the Department of Biotechnology (DBT) for second and third phase trials. If approved, Dr. Reddy’s will distribute the vaccine in the country. The third phase trials for Covaxin, which is being jointly developed by Bharat Biotech and the Indian Council of Medical Research, were already underway on a large sample size across 22 centres. Dr. Vardhan had gone on record to say that the COVID-19 vaccine will be available in the country in February or March 2021. Meanwhile, Prime Minister Narendra Modi will visit Pune, Ahmedabad and Hyderabad on November 28 to review coronavirus vaccine development at facilities there. The prime minister will be visiting the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute in Pune.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code